Skip to content
ClinCalc Pro
Menu
Progestogen (anti-mineralocorticoid, anti-androgenic)

Drospirenone

Brand names: Slynd (POP), Yasmin (with EE), Yaz (with EE), Eloine (with EE), Lucette (with EE)

Drospirenone is a progestogen with anti-mineralocorticoid and anti-androgenic activity, used in combined hormonal contraceptives and as a progestogen-only contraceptive pill.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It provides contraception chiefly by inhibiting ovulation, with additional effects on cervical mucus and the endometrium; its anti-mineralocorticoid action counteracts oestrogen-related fluid retention.

Prescribing in practice

  • Because of its anti-mineralocorticoid effect, use caution and consider potassium monitoring when co-prescribed with other potassium-raising drugs, as hyperkalaemia can occur.
  • When used in a combined preparation, the standard venous thromboembolism risks and contraindications of combined hormonal contraception apply.
  • The progestogen-only drospirenone pill provides an oestrogen-free option with a more forgiving missed-pill window than older progestogen-only pills.

Monitoring

Monitor blood pressure; consider checking serum potassium in women also taking other agents that raise potassium or with relevant renal impairment.

Counselling the patient

  • Take the pill regularly as directed and follow missed-pill advice for your specific product.
  • Report symptoms of a blood clot such as calf swelling, breathlessness or chest pain promptly.
  • Tell your clinician about other medicines, particularly those affecting potassium levels.

Evidence & guidelines

Drospirenone-containing contraceptives are established options within UK contraceptive guidance, with attention to thromboembolic and potassium-related considerations.

Reference: SmPC Slynd / Yasmin / Yaz; FSRH UK MEC 2016 (amended 2019); MHRA Drug Safety Update Feb 2014 (COCs and VTE); Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.